Fewer than one in 10 patients eligible to benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it releases its first recommendations on the drugs.
Considering over a billion individuals worldwide currently living with obesity, it is advocating for increased and just access to this class of drugs.
Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our latest guidance affirms that excess weight is a lifelong illness that can be addressed with holistic and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant hurdles to universal availability to the treatments that can assist patients in reducing considerable weight, says the agency.
Skinny Jab Scarcity
Even in the present most optimistic scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of eligible patients, as stated by the health organization.
The advice urges governments and firms to increase access, via strategies like voluntary licensing.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Operate
The injections imitate a body's own hormone to slow digestion, suppress the appetite and enhance the sense of being full so individuals consume fewer calories.
Patients typically see weight reduction in the initial weeks of beginning the regular doses.
Evidence points to users may see weight return within a year of halting the treatment, because their typical hunger resume.
Being above a healthy weight raises your chance for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the WHO.
